leadf
logo-loader
viewVolitionRx

VolitionRX encouraged by early data on its Nu.QTM blood test as potential tool against coronavirus

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive's Andrew Scott they've been investigating how its Nu.QTM platform might be clinically useful as either a diagnostic or prognostic tool for COVID-19 and that they've been encouraged by some of the early data.

He says they've recently conducted a proof of concept study involving 34 COVID-19 positive subjects and 50 control subjects.

The announcement was made alongside Volition's first quarter results which showed they ended the period with $12 million in cash and cash equivalents.

Quick facts: VolitionRx

Price: 2.99 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $142.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx hosts virtual capital markets day event to discuss upcoming...

VolitionRx Limited (NYSE AMERICAN: VNRX) CEO Cameron Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020. Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first...

1 week, 2 days ago

2 min read